Basilea Pharmaceutica AG (LON:0QNA)

Market Cap	486.49M
Revenue (ttm)	183.82M
Net Income (ttm)	68.40M
Shares Out	n/a
EPS (ttm)	5.13
PE Ratio	7.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,147
Average Volume	853
Open	44.50
Previous Close	44.68
Day's Range	44.90 - 45.80
52-Week Range	32.20 - 51.30
Beta	0.77
RSI	72.23
Earnings Date	Feb 18, 2025

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the compan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 147
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QNA

Financial Performance

In 2024, Basilea Pharmaceutica AG's revenue was 208.54 million, an increase of 32.30% compared to the previous year's 157.63 million. Earnings were 77.59 million, an increase of 642.45%.

Financial numbers in CHF